• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于手术切除边缘状态的复发性直肠癌患者生存的荟萃分析。

Meta-analysis of survival based on resection margin status following surgery for recurrent rectal cancer.

机构信息

Department of Colorectal Surgery, Royal Marsden Hospital, Fulham Road, London, UK.

出版信息

Colorectal Dis. 2012 Dec;14(12):1457-66. doi: 10.1111/j.1463-1318.2012.03005.x.

DOI:10.1111/j.1463-1318.2012.03005.x
PMID:22356246
Abstract

AIM

To determine the presence and duration of survival advantages was investigated for resection margin status (R0, R1 or R2) following surgery for locally recurrent rectal cancer (LRRC).

METHOD

A systematic review of the literature was performed for studies comparing resection margin status for LRRC. Weighted mean differences and meta-analysis of hazard ratios were used as a measure of median and overall cumulative survival.

RESULTS

Twenty-two studies were included, providing outcome for 1460 patients undergoing surgery for LRRC. 57% underwent an R0 resection, 25% an R1 resection and 11% an R2 resection. The most commonly performed operations were abdominoperineal excision (35%), exenteration (23%) and anterior resection (21%). The range of median survival per resection margin was R0 28-92 months, R1 12-50 months, R2 6-17 months. Patients undergoing an R0 resection survived on average for 37.6 (95% confidence interval: 23.5-51.7) months longer than those undergoing R1 resection and 53.0 (31.2-74.8) months longer than those undergoing R2 resection. This correlated to a hazard ratio of 2.03 (1.73-2.38) for R0 vs R1 and 3.41 (2.21-5.25) for R0 vs R2. Patients undergoing R1 resection survived on average 13.3 (7.23-19.4) months longer than those undergoing R2 resection [hazard ratio of 1.68 (1.33-2.12)].

CONCLUSION

Patients undergoing R0 resection have the greatest survival advantage following surgery for recurrent rectal cancer. There is a survival advantage for R1 over R2 resection, but there may be no benefit of R2 resection over palliative treatment.

摘要

目的

研究局部复发性直肠癌(LRRC)手术后的切缘状态(R0、R1 或 R2)对生存优势的存在和持续时间。

方法

对比较 LRRC 切缘状态的研究进行了系统的文献回顾。使用加权平均差异和危险比的荟萃分析作为衡量中位和总累积生存的指标。

结果

共纳入 22 项研究,为 1460 例接受 LRRC 手术的患者提供了结果。57%的患者行 R0 切除术,25%行 R1 切除术,11%行 R2 切除术。最常施行的手术为腹会阴切除术(35%)、前切除术(21%)和直肠前切除术(21%)。每种切缘状态的中位生存时间范围分别为 R0 28-92 个月、R1 12-50 个月、R2 6-17 个月。R0 组患者的平均生存时间比 R1 组长 37.6 个月(95%置信区间:23.5-51.7),比 R2 组长 53.0 个月(31.2-74.8)。这对应于 R0 与 R1 相比的危险比为 2.03(1.73-2.38),R0 与 R2 相比的危险比为 3.41(2.21-5.25)。R1 组患者的平均生存时间比 R2 组长 13.3 个月(7.23-19.4),危险比为 1.68(1.33-2.12)。

结论

R0 切除术后的患者在复发性直肠癌手术后具有最大的生存优势。R1 切除比 R2 切除有生存优势,但 R2 切除与姑息治疗相比可能没有获益。

相似文献

1
Meta-analysis of survival based on resection margin status following surgery for recurrent rectal cancer.基于手术切除边缘状态的复发性直肠癌患者生存的荟萃分析。
Colorectal Dis. 2012 Dec;14(12):1457-66. doi: 10.1111/j.1463-1318.2012.03005.x.
2
What Constitutes a Clear Margin in Patients With Locally Recurrent Rectal Cancer Undergoing Pelvic Exenteration?行盆腔廓清术的局部复发性直肠癌患者的“切缘清晰”如何定义?
Ann Surg. 2022 Jan 1;275(1):157-165. doi: 10.1097/SLA.0000000000003834.
3
[Analysis on risk factors of the degree of radical resection and prognosis of patients with locally recurrent rectal cancer].[局部复发性直肠癌患者根治性切除程度及预后的危险因素分析]
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 May 25;23(5):472-479. doi: 10.3760/cma.j.cn.441530-20200207-00042.
4
Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer.影响局部复发性直肠癌盆腔廓清术后结局的因素。
Br J Surg. 2018 May;105(6):650-657. doi: 10.1002/bjs.10734. Epub 2018 Mar 12.
5
Effect of Surgery on Health-Related Quality of Life of Patients With Locally Recurrent Rectal Cancer.手术对局部复发性直肠癌患者健康相关生活质量的影响。
Dis Colon Rectum. 2015 Aug;58(8):753-61. doi: 10.1097/DCR.0000000000000403.
6
Early and Late Outcomes of Surgery for Locally Recurrent Rectal Cancer: A Prospective 10-Year Study in the Total Mesorectal Excision Era.局部复发性直肠癌手术的早期和晚期结果:全直肠系膜切除时代的一项前瞻性10年研究。
Ann Surg Oncol. 2015 Aug;22(8):2677-84. doi: 10.1245/s10434-014-4317-y. Epub 2015 Jan 7.
7
Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.术前超分割放化疗用于既往盆腔放疗后的局部复发性直肠癌患者:一项多中心II期研究。
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. doi: 10.1016/j.ijrobp.2005.09.017. Epub 2006 Jan 18.
8
Indications and outcome of pelvic exenteration for locally advanced primary and recurrent rectal cancer.盆腔廓清术治疗局部晚期原发性和复发性直肠癌的适应证和结果。
Ann Surg. 2014 Feb;259(2):315-22. doi: 10.1097/SLA.0b013e31828a0d22.
9
Management and prognosis of locally recurrent rectal cancer - A national population-based study.局部复发性直肠癌的管理与预后——一项基于全国人群的研究。
Eur J Surg Oncol. 2018 Jan;44(1):100-107. doi: 10.1016/j.ejso.2017.11.013. Epub 2017 Nov 26.
10
Abdominoperineal resection for locally recurrent rectal cancer.局部复发性直肠癌的腹会阴联合切除术
Tech Coloproctol. 2001 Aug;5(2):97-102. doi: 10.1007/pl00012131.

引用本文的文献

1
The rise of robotics: Surgical approaches for rectal cancer over time.机器人技术的兴起:直肠癌手术方法的演变
Surg Endosc. 2025 Aug 25. doi: 10.1007/s00464-025-12065-w.
2
Prospective longitudinal trajectory of cancer survivorship among patients with recurrent rectal cancer: impact of treatment modalities and resection status.复发性直肠癌患者癌症幸存者的前瞻性纵向轨迹:治疗方式和切除状态的影响
Colorectal Dis. 2025 May;27(5):e70110. doi: 10.1111/codi.70110.
3
Multidisciplinary approach to target volume delineation in locally recurrent rectal cancer: An explorative study.
局部复发性直肠癌靶区勾画的多学科方法:一项探索性研究。
Clin Transl Radiat Oncol. 2025 Apr 1;53:100948. doi: 10.1016/j.ctro.2025.100948. eCollection 2025 Jul.
4
Operative Strategies for Beyond Total Mesorectal Excision Surgery for Rectal Cancer.直肠癌全直肠系膜切除术后的手术策略
Ann Surg Oncol. 2025 Jun;32(6):4240-4249. doi: 10.1245/s10434-025-17151-w. Epub 2025 Mar 18.
5
Margin matters: analyzing the impact of circumferential margin involvement on survival and recurrence after incomplete total mesorectal excision for rectal cancer.切缘很重要:分析环周切缘受累对直肠癌全直肠系膜切除不完整术后生存和复发的影响。
Tech Coloproctol. 2025 Jan 23;29(1):50. doi: 10.1007/s10151-024-03098-9.
6
Radiotherapy & total neoadjuvant therapy for recurrent rectal cancer in previously irradiated patients, (RETRY): a multicenter prospective observational study.先前接受过放疗的复发性直肠癌患者的放疗与全新辅助治疗(RETRY):一项多中心前瞻性观察研究
Radiat Oncol. 2024 Dec 18;19(1):174. doi: 10.1186/s13014-024-02555-x.
7
Priority outcomes of pelvic exenteration for rectal cancer: a patient, carer, and clinician consensus.直肠癌盆腔廓清术的优先结局:患者、照料者及临床医生的共识
Br J Surg. 2024 Nov 27;111(12). doi: 10.1093/bjs/znae298.
8
Advances in beyond total mesorectal excision surgery: Behind the scenes.全直肠系膜切除术后手术进展:幕后故事
World J Gastrointest Surg. 2024 Nov 27;16(11):3381-3384. doi: 10.4240/wjgs.v16.i11.3381.
9
Proton beam reirradiation for locally recurrent rectal cancer patients with prior pelvic irradiation.质子束再放疗用于既往盆腔放疗的局部复发性直肠癌患者。
J Radiat Res. 2024 May 23;65(3):379-386. doi: 10.1093/jrr/rrae019.
10
Beyond Total Mesorectal Excision (TME)-Results of MRI-Guided Multivisceral Resections in T4 Rectal Carcinoma and Local Recurrence.超越全直肠系膜切除术(TME)——T4期直肠癌MRI引导下多脏器切除术及局部复发的结果
Cancers (Basel). 2023 Nov 8;15(22):5328. doi: 10.3390/cancers15225328.